Wpływ neuropeptydu Y na regulację czynności układu krążenia

• Authors: Ryszard Swoboda , Jerzy Jochem

Title variants

EO

The influence of neuropeptide Y on the cardiovascular regulation

• Languages of publication: PL

Abstracts

PL

W niniejszej pracy przedstawiono wpływ neuropeptydu Y (NPY), peptydu zbudowanego z 36 aminokwasów, należącego do rodziny polipeptydów trzustkowych, na ośrodkową oraz obwodową regulację układu krążenia. NPY jest obecny w wielu obszarach ośrodkowego układu nerwowego, takich jak jądra łukowate, przykomorowe podwzgórza, jądro pasma samotnego (NTS) czy też przednia brzuszno-boczna część rdzenia przedłużonego (RVLM). Ponadto jest on uwalniany z pozazwojowych neuronów układu współczulnego oraz z płytek krwi. NPY działa zarówno w ośrodkowym, jak i obwodowym układzie nerwowym jako neuromodulator uwalniany łącznie z klasycznymi neurotransmiterami. Wpływa on na funkcje ośrodka sercowo-naczynioruchowego w sposób bezpośredni, działając na RVLM oraz neurony podwzgórza, jak również pośrednio, poprzez wpływ na czułość odruchu z baroreceptorów tętniczych na poziomie NTS. Co ciekawe, aktywacja różnych typów receptorów NPY w ośrodkowym układzie nerwowym może powodować różne, a nawet przeciwstawne efekty w regulacji czynności układu krążenia. W stanie zaburzonej homeostazy krążeniowej, np. podczas wstrząsu krwotocznego, dochodzi do wzrostu syntezy i uwalniania NPY, który prawdopodobnie aktywuje mechanizmy kompensacyjne prowadzące do utrzymania niezbędnych do przeżycia wartości ciśnienia krwi. Przedstawiona analiza wskazuje na konieczność prowadzenia dalszych badań nad rolą NPY w stanie hiper- i hipotensji.

EN

In this review we present infl uences of the neuropeptide Y (NPY), a 36-amino acid peptide which belongs to the pancreatic polypeptide family, on the central and peripheral cardiovascular regulation. NPY has been detected in many central nervous system areas, including arcuate and paraventricular nuclei of the hypothalamus, nucleus of the solitary tract (NTS) and rostral ventral-lateral medulla (RVLM). Moreover, it is released from postganglionic neurons of the sympathetic nervous system and platelets. Both at the central and peripheral level, NPY acts as a peptide neuromodulator secreted together with classical neurotransmitters. It infl uences the cardiovascular center function acting directly on RVLM and hypothalamic neurons and indirectly – via regulation of the baroreceptor refl ex sensitivity at NTS level. Interestingly, the activation of diff erent types of NPY receptors in diff erent central nervous system areas can cause various, even opposite, eff ects in the cardiovascular regulation. There is an increase in NPY synthesis and release in conditions of disturbed circulatory homeostasis, for instance in haemorrhagic shock. In critical haemorrhagic hypotension, NPY probably activates compensatory mechanisms leading to maintenance of blood pressure values necessary to survive. Thus, we conclude that further studies are needed to clarify NPY functions in conditions of hyper- and hypotension.

Keywords

EN

cardiovascular system; hipotensja; hypotension; hypothalamus; neuropeptide Y; neuropeptyd Y; podwzgórze; układ krążenia

Discipline

• MEDICINE: MEDICINE

• Publisher: Śląski Uniwersytet Medyczny w Katowicach
• Journal: Annales Academiae Medicae Silesiensis
• Year: 2010
• Volume: 64
• Issue: 5-6
• Pages: 82-88

Contributors

author

Ryszard Swoboda

• Katedra i Zakład Podstawowych Nauk Medycznych Śląskiego Uniwersytetu Medycznego w Katowicach

author

Jerzy Jochem

• Katedra i Zakład Podstawowych Nauk Medycznych Śląski Uniwersytet Medyczny w Katowicach, ul. Piekarska 18, 41-902 Bytom, tel./fax [phone]

References

• 1. Tatemoto K., Carlquist M., Mutt V. Neuropeptide Y – a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982; 296: 659-660.
• 2. Zoccali C. Neuropeptide Y as a far-reaching neuromediator: from energy balance and cardiovascular regulation to central integration of weight and bone mass control mechanisms. Implications for human diseases. Curr. Opin. Nephrol. Hypertens. 2005; 14: 25–32.
• 3. Michel M.C., Beck-Sickinger A., Cox H. i wsp. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 1998; 50: 143–150.
• 4. Perney T.M., Miller R.J. Two diff erent G-proteins mediate neuropeptide Y and bradykinin-stimulated phospholipid breakdown in cultured rat sensory neurons. J. Biol. Chem. 1989; 264: 7317–7327.
• 5. Myers A.K., Farhat M.Y., Vaz C.A. i wsp. Release of immunoreactive-neuropeptide by rat platelets. Biochem. Biophys. Res. Commun. 1988; 155: 118–122.
• 6. Morris M.J., Tortelli C.F., Hart D.P., Delbridge L.M. Vascular and brain neuropeptide Y in banded and spontaneously hypertensive rats. Peptides 2004; 25: 1313–1319.
• 7. Ciarleglio A.E., Beinfeld M.C., Westfall T.C. Pharmacological characterization of the release of neuropeptide Y-like immunoreactivity from the rat hypothalamus. Neuropharmacology 1993; 32: 819–825.
• 8. Maurelli M., Marchioni E., Tartara A. Involvement of catecholaminergic transmission in neurophysiological responses to centrally administered NPY. Boll. Soc. Ital. Biol. Sper. 1993; 69: 187–193.
• 9. Dumont Y., Martel J.C., Fournier A. i wsp. Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. Prog. Neurobiol. 1992; 38: 125–167.
• 10. Potter E.K. Neuropeptide Y as an autonomic neurotransmitter. Pharmacol. Ther. 1988; 37: 251–273.
• 11. Clark J.T., Kalra P.S., Kalra S.P. Neuropeptide Y stimulates feeding but inhibits sexual behavior in rats. Endocrinology 1985; 117: 2435–2442.
• 12. Fuxe K., Agnati L.F., Härfstrand A. i wsp. Central administration of neuropeptide Y induces hypotension bradypnea and EEG synchronization in the rat. Acta Physiol. Scand. 1983; 118: 189–192.
• 13. Tanida M., Shen J., Nagai K. Possible role of the histaminergic system in autonomic and cardiovascular responses to neuropeptide Y. Neuropeptides 2009; 43: 21–29.
• 14. Humphreys G.A., Davison J.S., Veale W.L. Hypothalamic neuropeptide Y inhibits gastric acid output in rat: role of the autonomic nervous system. Am. J. Physiol. 1992; 263: G726–G732.
• 15. Savaki H.E., Macpherson H., McCulloch J. Alterations in local cerebral glucose utilization during hemorrhagic hypotension in the rat. Circ. Res. 1982; 50: 633–644.
• 16. Barraco R.A., Ergene E., Dunbar J.C. i wsp. Cardiorespiratory response patterns elicited by microinjections of neuropeptide Y in the nucleus tractus solitarius. Brain Res. Bull. 1990; 24: 465–485.
• 17. Kashihara K., McMullan S., Lonergan T. i wsp. Neuropeptide Y in the rostral ventrolateral medulla blocks somatosympathetic refl exes in anesthetized rats. Auton. Neurosci. 2008; 142: 64–70.
• 18. Hua X.Y., Boublik J.H., Spicer M.A. i wsp. The antinociceptive eff ects of spinally administered neuropeptide Y in the rat: systematic studies on structure-activity relationship. J. Pharmacol. Exp. Ther. 1991; 258: 243–248.
• 19. Hu Y., Dunbar J.C. Intracerebroventricular administration of NPY increases sympathetic tone selectively in vascular beds. Brain Res. Bull. 1997; 44: 97–103.
• 20. Matsumura K., Tsuchihashi T., Abe I. Central cardiovascular action of neuropeptide Y in conscious rabbits. Hypertension 2000; 36: 1040–1044.
• 21. Vallejo M., Lightman S.L. Pressor eff ect of centrally administered neuropeptide Y in rats: role of sympathetic nervous system and vasopressin. Life Sci. 1986; 38: 1859–1866.
• 22. Martin J.R. Neuropeptide Y potentiates the pressor response evoked by carbachol administration into the posterior hypothalamic nucleus of conscious rat. Brain Res. 2002; 949: 79-87.
• 23. Yang S.N., Yang W., Tang Y.H., Wang S. Cardiovascular eff ects of intracerebral injection of neuropeptide Y in rats. Zhongguo. Yao. Li. Xue. Bao. 1992; 13: 116–118.
• 24. Aguirre J.A., Fuxe K., Hedlund P. i wsp. Neuropeptide Y/angiotensin II interactions in central cardiovascular regulation of the rat. Brain Res. 1991; 566: 61–69.
• 25. Yang S.N., Fior D.R., Hansson A.C. i wsp. Increased potency of neuropeptide Y to antagonize alpha2-adrenoceptor function in the nucleus tractus solitarii of the spontaneously hypertensive rat. Neuroscience 1997; 78: 803–813.
• 26. Grundemar L., Wahlestedt C., Reis D.J. Long-lasting inhibition of the cardiovascular responses to glutamate and the baroreceptor refl ex elicited by neuropeptide Y injected into the nucleus tractus solitarius of the rat. Neurosci. Lett. 1991; 122: 135– 139.
• 27. McAuley M.A., Macrae I.M., Reid J.L. The cardiovascular actions of clonidine and neuropeptide-Y in the ventrolateral medulla of the rat. Br. J. Pharmacol. 1989; 97: 1067–1074.
• 28. Mahinda T.B., Taylor B.K. Intrathecal neuropeptide Y inhibits behavioral and cardiovascular responses to noxious infl ammatory stimuli in awake rats. Physiol. Behav. 2004; 80: 703–711.
• 29. Michalkiewicz M., Knestaut K.M., Bytchkova E.Y., Michalkiewicz T. Hypotension and reduced catecholamines in neuropeptide Y transgenic rats. Hypertension 2003; 41: 1056–1062.
• 30. Coelho E.F., Ferrari M.F., Maximino J.R., Fior-Chadi D.R. Change in the expression of NPY receptor subtypes Y1 and Y2 in central and peripheral neurons related to the control of blood pressure in rats following experimental hypertension. Neuropeptides 2004; 38: 77–82.
• 31. Shih C.D., Chan J.Y., Chan S.H. Tonic suppression of baroreceptor refl ex response by endogenous neuropeptide Y at the nucleus tractus solitarius of the rat. Neurosci Lett. 1992; 148: 169–172.
• 32. Fuxe K., Härfstrand A., Agnati L.F. i wsp. Central catecholamine-neuropeptide Y interactions at the pre- and postsynaptic level in cardiovascular centers. J. Cardiovasc. Pharmacol. 1987; 10: S1–S13.
• 33. Ouyang M., Wang S. Dexamethasone attenuates the depressor response induced by neuropeptide Y microinjected into the nucleus tractus solitarius in rats. Br. J. Pharmacol. 2000; 129: 865–870.
• 34. Díaz-Cabiale Z., Parrado C., Rivera A. i wsp. Galanin-neuropeptide Y (NPY) interactions in central cardiovascular control: involvement of the NPY Y receptor subtype. Eur. J. Neurosci. 2006; 24: 499– 508.
• 35. Lee J., Morris M.J. Modulation of neuropeptide Y overfl ow by leptin in the rat hypothalamus, cerebral cortex and medulla. Neuroreport. 1998; 9: 1575–1580.
• 36. Velkoska E., Cole T.J., Morris M.J. Early dietary intervention: long-term eff ects on blood pressure, brain neuropeptide Y, and adiposity markers. Am. J. Physiol. Endocrinol. Metab. 2005; 288: E1236–E1243.
• 37. Hoyda T.D., Smith P.M., Ferguson A.V. Adiponectin acts in the nucleus of the solitary tract to decrease blood pressure by modulating the excitability of neuropeptide Y neurons. Brain Res. 2009; 1256: 76–84.
• 38. Díaz-Cabiale Z., Fuxe K., Coveñas R. i wsp. Angiotensin II modulates the cardiovascular responses to microinjection of NPY Y1 and NPY Y2 receptor agonists into the nucleus tractus solitarii of the rat. Brain Res. 2003; 983: 193–200.
• 39. McLean K.J., Jarrott B., Lawrence A.J. Hypotension activates neuropeptide Y-containing neurons in the rat medulla oblongata. Neuroscience 1999; 92: 1377–1387.
• 40. Li Q., Goodchild A.K., Pilowsky P.M. Eff ect of haemorrhage on the expression of neurotransmitter-related genes in rat ventrolateral medulla: a quantitative real-time RT-PCR study. Brain Res. Mol. Brain Res. 2003; 114: 46–54.
• 41. Michalkiewicz M., Michalkiewicz T., Kreulen D.L., McDougall S.J. Increased blood pressure responses in neuropeptide Y transgenic rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001; 281: R417– R426.
• 42. Zukowska-Grojec Z., Karwatowska- Prokopczuk E., Rose W. i wsp. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ. Res. 1998; 83: 187–195.
• 43. Mentlein R., Roos T. Proteases involved in the metabolism of angiotensin II, bradykinin, calcitonin gene-related peptide (CGRP), and neuropeptide Y by vascular smooth muscle cells. Peptides 1996; 17: 709–720.
• 44. MacLean M.R., Hiley C.R. Eff ect of neuropeptide Y on cardiac output, its distribution, regional blood fl ow and organ vascular resistances in the pithed rat. Br. J. Pharmacol. 1990; 99: 340–342.
• 45. Millar B.C., Weis T., Piper H.M. i wsp. Positive and negative contractile eff ects of neuropeptide Y on ventricular cardiomyocytes. Am. J. Physiol. 1991; 261: H1727– H1733.
• 46. Morris M.J., Russell A.E., Kapoor V. i wsp. Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. J. Auton. Nerv. Syst. 1986; 17: 143–149.
• 47. Zukowska-Grojec Z., Konarska M., McCarty R. Diff erential plasma catecholamine and neuropeptide Y responses to acute stress in rats. Life Sci. 1988; 42: 1615–1624.
• 48. Grouzmann E., Comoy E., Bohuon C. Plasma neuropeptide Y concentrations in patients with neuroendocrine tumors. J. Clin. Endocrinol. Metab. 1989; 68: 8808– 8813.
• 49. Zoccali C., Mallamaci F., Tripepi G. i wsp. Prospective study of neuropeptide Y as an adverse cardiovascular risk factor in end-stage renal disease. J. Am. Soc. Nephrol. 2003; 14: 2611–2617.
• 50. Qureshi N.U., Dayao E.K., Shirali S. i wsp. Endogenous neuropeptide Y mediates vasoconstriction during endotoxic and hemorrhagic shock. Regul. Pept. 1998; 75-76: 215–220.
• 51. Rudehill A., Olcén M., Sollevi A. i wsp. Release of neuropeptide Y upon haemorrhagic hypovolaemia in relation to vasoconstrictor eff ects in the pig. Acta Physiol. Scand. 1987; 131: 517–523.

• Document Type: article